Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1998-2-12
|
| pubmed:abstractText |
To assess the effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on plasma cholesterol concentrations and on platelet aggregation, lovastatin or fluvastatin, 40 mg daily, was given to hypercholesterolemic patients. After 24 weeks, plasma low-density lipoprotein (LDL) cholesterol concentrations were reduced by 37% after lovastatin therapy and 29% after fluvastatin therapy. The platelet cholesterol/phospholipid ratio was reduced by 33% and 26%, respectively. Platelet aggregation was significantly reduced by 12-15% (p < 0.01) after 4 weeks of therapy with either agent. Lovastatin or fluvastatin therapy reduced platelet aggregation through an in vivo hypocholesterolemic action on the platelet cholesterol content and also through a direct effect on platelet function, as a result of drug binding to the platelets. We also studied the effect of these HMG-CoA reductase inhibitors on LDL susceptibility to oxidation. LDL oxidation (induced by copper ions) was reduced by 31% after lovastatin therapy and by 37% after fluvastatin therapy. The inhibitory effect of HMG-CoA reductase inhibitors on LDL oxidation involved their stimulatory effect on the removal of LDL from the circulation and a direct binding effect of the drugs to the lipoprotein. Because HMG-CoA reductase inhibitors can inhibit platelet aggregation, macrophage foam cell formation, and LDL oxidation, major contributors to atherogenesis, the use of these drugs can significantly attenuate the atherosclerotic process.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticholesteremic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Fatty Acids, Monounsaturated,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxymethylglutaryl-CoA...,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Lovastatin,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/fluvastatin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0160-2446
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
31
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
39-45
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9456275-Adult,
pubmed-meshheading:9456275-Aged,
pubmed-meshheading:9456275-Animals,
pubmed-meshheading:9456275-Anticholesteremic Agents,
pubmed-meshheading:9456275-Blood Platelets,
pubmed-meshheading:9456275-Cell Communication,
pubmed-meshheading:9456275-Fatty Acids, Monounsaturated,
pubmed-meshheading:9456275-Humans,
pubmed-meshheading:9456275-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:9456275-Hypercholesterolemia,
pubmed-meshheading:9456275-Indoles,
pubmed-meshheading:9456275-Lipid Peroxidation,
pubmed-meshheading:9456275-Lipoproteins,
pubmed-meshheading:9456275-Lipoproteins, LDL,
pubmed-meshheading:9456275-Lovastatin,
pubmed-meshheading:9456275-Macrophages,
pubmed-meshheading:9456275-Mice,
pubmed-meshheading:9456275-Middle Aged,
pubmed-meshheading:9456275-Platelet Activation,
pubmed-meshheading:9456275-Platelet Aggregation,
pubmed-meshheading:9456275-Platelet Aggregation Inhibitors
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
|
| pubmed:affiliation |
Lipid Research Laboratory, Rambam Medical Center, The Bruce Rappaport Faculty of Medicine, Technion, Israel.
|
| pubmed:publicationType |
Journal Article
|